challenges and future perspectives for minimal residual disease (mrd) in multiple myeloma
Published 7 years ago • 738 plays • Length 11:23Download video MP4
Download video MP3
Similar videos
-
3:35
minimal residual disease (mrd) as a prognostic factor for acute myeloid leukemia (aml)
-
1:39
minimal residual disease (mrd) monitoring for multiple myeloma is here to stay
-
1:26
mrd in myeloma: the fda perspective
-
3:36
minimal residue disease (mrd) in multiple myeloma
-
3:40
what’s new in minimal residual disease (mrd) detection in myeloma?
-
4:05
are we ready to use minimal residual disease (mrd) to direct multiple myeloma therapy?
-
0:38
challenges in managing patients with multiple myeloma: the nursing perspective
-
13:08
debate on the use of mrd for multiple myeloma management
-
1:16
perspectives on the role of mrd negativity in multiple myeloma
-
2:05
emerging therapeutic challenges to treating patients with multiple myeloma
-
2:31
key challenges in the management of extramedullary and cns disease in patients with multiple myeloma
-
3:23
a bright future for multiple myeloma
-
1:37
mrd in myeloma
-
2:46
managing patients with high-risk myeloma
-
2:01
the role of mrd in cll patients with high-risk cytogenetics & future perspectives
-
2:07
advancements in clinical trials for high-risk newly diagnosed multiple myeloma
-
3:58
what role will minimal residual disease testing play in multiple myeloma?
-
1:57
challenges in treating frail, older patients with myeloma: high-risk patients & toxicity management
-
2:00
the potential of studying circulating plasma cells in multiple myeloma